### Contents

**Contributors**

*Preface*  
ix

1. **Challenges in progressing cell therapies to the clinic for Huntington's disease: A review of the progress made with pluripotent stem cell derived medium spiny neurons**  
Patricia Garcia Jareño, Oliver J.M. Bartley, Sophie V. Precious, Anne E. Rosser, and Mariah J. Lelos  
1

1. Introduction  
2. Derivation of MSN-like cells from hPSCs: What has been shown *in vitro and in vivo*?  
3. Evidence for functional recovery following CRT and underlying mechanisms  
4. Challenges  
5. Conclusions and authors perspectives  
References  
41

2. **Challenges of cell therapies for retinal diseases**  
Monville Christelle, Morizur Lise, and Karim Ben M'Barek  
49

1. Introduction  
2. Retinal disorders: Focus on AMD and RP  
3. Human pluripotent stem cells for retinal cell therapy  
4. Transposing bench-scale practices to industrialization  
5. Conclusion  
Funding Statement  
References  
66

3. **Cell transplantation to repair the injured spinal cord**  
Adam Hall, Tara Fortino, Victoria Spruance, Alessia Niceforo, James S. Harrop, Patricia E. Phelps, Catherine A. Priest, Lyandysha V. Zholudeva, and Michael A. Lane  
79

1. Introduction  
2. Transplantation for spinal cord repair  
3. Pro-regenerative transplants: Bridging for spinal cord repair  
83
4. Investigating cell therapies in animal models of Parkinson's and Huntington's disease: Current challenges and considerations 159
   Mariah J. Lelos
   1. Introduction 160
   2. Challenge 1: Identifying a good model for cell transplantation studies 162
   3. Challenge 2: Survival of xenografts in rodent models 170
   5. Challenge 4: Creating clinically relevant models 178
   6. Discussion 182
   References 183

5. Considerations for the use of biomaterials to support cell therapy in neurodegenerative disease 191
   Victoria H. Roberton and James B. Phillips
   1. Using biomaterials to support cell therapies 192
   2. Considerations for the use of biomaterials 193
   3. Promising biomaterial and cell based therapies for neurodegenerative disease 200
   4. Clinical translation 201
   5. Conclusion 202
   References 203

6. Challenges of translating a cell therapy to GMP 207
   Gerhard Bauer and Brian Fury
   1. The history of cell and gene therapy manufacturing 208
   2. Characterization of the NSCs 220
   3. History and track record 230
   4. QC/QA at the UC Davis GMP facility 230
   References 233
## Contents

7. **Considerations for clinical trial design and conduct in the evaluation of novel advanced therapeutics in neurodegenerative disease**
   Cheney J.G. Drew and Monica Busse
   
   1. Introduction ........................................... 236
   2. Principles of clinical trial design ................. 239
   3. Outcome measures in cell and gene therapy trials in neurodegenerative disease ....... 248
   4. Technical and practical factors for consideration in operationalizing the intracranial delivery of cell and gene therapies .... 258
   5. Considerations for the inclusion of participants in trials of cell and gene therapies .. 262
   6. Summary ............................................ 267
   References .............................................. 267

8. **More than a participant in trials of cell and gene therapy: Hearing the voices of people living with neurodegenerative diseases**
   Emma L. Lane, Lyndsey Isaacs, and Soania Mathur
   
   1. Introduction ........................................... 282
   2. Public and patient perceptions of cell and gene therapy ................. 284
   3. The experiences of clinical trial participants with neurodegenerative diseases .... 287
   4. How is the voice of those living with degenerative disease engaged with? ....... 299
   5. Factors that contribute to a meaningful patient voice .................. 304
   6. The patient voice in clinical delivery ................................ 305
   7. Conclusion ............................................ 306
   Acknowledgments ........................................ 306
   The authors ............................................ 306
   References .............................................. 306